Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
暂无分享,去创建一个
T. Mikkelsen | W. Yung | M. Prados | P. Wen | T. Cloughesy | D. Schiff | H. Friedman | M. Nicholas | W. Yung | L. Abrey | R. Jensen | J. Vredenburgh | N. Paleologos | Jane E. Huang | M. Zheng | Lauren E. Abrey | Michael D. Prados | W.K. Alfred Yung | Henry S. Friedman | Patrick Y. Wen | Martin K. Nicholas
[1] T. Cloughesy,et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. , 2008, International journal of radiation oncology, biology, physics.
[2] Timothy F Cloughesy,et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.
[3] Harsh V Jain,et al. Modeling the VEGF–Bcl-2–CXCL8 Pathway in Intratumoral Agiogenesis , 2008, Bulletin of mathematical biology.
[4] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[5] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[7] J. Buckner,et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.
[8] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[9] Susan M. Chang,et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2006, Neuro-oncology.
[10] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[11] David M Jablons,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Henriksson,et al. Spatial Expression of VEGF-A in Human Glioma , 2002, Journal of Neuro-Oncology.
[13] Eytan Domany,et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. , 2003, Cancer research.
[14] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[15] C. N. Coleman,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[16] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[17] T. Cloughesy,et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen , 2003, Cancer.
[18] E. Raymond,et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] M. Westphal,et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[21] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[22] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[23] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. McLendon,et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Westphal,et al. Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. , 1993, International journal of oncology.
[26] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[27] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] George Casella,et al. Refining binomial confidence intervals , 1986 .
[29] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .